Navigation Links
Ayurvedic nightshade deadly for dengue mosquito

Mosquitoes responsible for spreading disease are increasingly becoming resistant to synthetic insecticides. Now research published in the online open access journal BMC Complementary and Alternative Medicine suggests that the berries of a weed common to India, Solanum villosum (S villosum), have potential for keeping mosquitoes at bay.

S. villosum is a member of the nightshade family known for its medicinal properties and commonly used as an ayurvedic herb.

Nandita Chowdhury, Anupam Ghosh and Goutam Chandra from Burdwan University, West Bengal, India used juice and extracts from the berries of S. villosum, on Stegomyia aegypti, (S. aegypti), which can spread a number of viruses including dengue fever and yellow fever and is commonly known as the yellow fever mosquito.

The authors found that S. villosum was particularly effective at eliminating S. aegypti larvae. Although it was not as potent as a chemical insecticide such as Malathion, the authors suggest that plant extracts from S. villosum have the potential for use in stagnant water where the mosquitoes breed. The next step is to identify the active compounds in the berries and to test whether these are effective in field trials.

We found that these plants produce two types of phytochemicals. says Chandra. The most interesting are the secondary phytochemicals, such as steroids, terpenoids, flavonoids and alkaloids these act as a repellent which protect against the lethal effects of the larval mosquitoes.

A number of plants have been reported for their anti-mosquito activity. Most of the studies report the active compounds to be steroidal saponins, which are thought to kill larvae by interfering with their cuticle membranes. However, only a few botanicals have moved from the laboratory to field use.

Around two-fifths of the Worlds population is at risk from dengue fever, which is characterized by a high fever, pain and rashes. Dengue hemorrhagic fever is a potentially lethal complication, affecting mainly children.


Contact: Charlotte Webber
BioMed Central

Related biology news :

1. Deadly genetic disease prevented before birth in zebrafish
2. Research unveils new hope for deadly childhood disease
3. Best treatment identified to reduce deadly Staph infections
4. Northwestern to expose most deadly infectious diseases in 3-D
5. Scripps research team blocks bacterial communication system to prevent deadly staph infections
6. Netting mosquitoes to prevent malaria
7. Researchers put the bite on mosquitoes
8. Earlier bites by uninfected mosquitoes boost West Nile deaths in lab mice
9. USDA Cooperative Agreement funds mosquito project at Rutgers
10. Advance in effort to fight malaria by tricking the mosquitos sense of smell
Post Your Comments:
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced expansion of its TDDI ... touch controller and display driver integration (TDDI) ... smartphones. These new TDDI products add to the ... resolution), TD4302 (WQHD resolution), and TD4322 (FHD resolution) ...
(Date:11/11/2015)... Nov. 11, 2015   MedNet Solutions , an innovative ... clinical research, is pleased to announce that it will be ... (PCT) event, to be held November 17-19 in ... view live demonstrations of iMedNet , MedNet,s ... iMedNet has been able to deliver time and ...
(Date:11/9/2015)... SAN JOSE, Calif. , Nov. 9, 2015 /PRNewswire/ ... of human interface solutions, today announced broader entry into ... of vehicle-specific solutions that match the pace of consumer ... drivers, and biometric sensors are ideal for the automotive ... the vehicle. Europe , ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... ANGELES and HOLLISTON, Mass. ... Technology, Inc. (Nasdaq: HART ), a biotechnology company ... that CEO Jim McGorry will present at ... December 1, 2015 at 2:30 p.m. PT. The presentation ... below) for 30 days. Management will also be available ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris ... that its business and prospects remain fundamentally strong ... Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation to ... completion following review of the final interim efficacy ... 2 Primary Endpoint in men with heavily pretreated ...
(Date:11/25/2015)... 25, 2015 Orexigen® Therapeutics, Inc. (Nasdaq: ... a fireside chat discussion at the Piper Jaffray 27th ... . The discussion is scheduled for Wednesday, December 2, ... .  A replay will be available for 14 days ... , Julie NormartVP, Corporate Communications and Business Development , ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
Breaking Biology Technology: